◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocks › TECH

Bio-Techne Corp (TECH) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · Life Sciences Tools & Services · DATA UPDATED 2026-07-19

Bio-Techne Corp (TECH) operates in the Life Sciences Tools & Services industry and is headquartered in Minneapolis, United States with about 3,100 employees. Its market capitalization is roughly $11 billion. In the fiscal year ended 2025-06-30, TECH reported $1.2B in revenue and $73M in net income.

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology.

Interactive charts & full statements → Open the TECH valuation workbench →

TECH Revenue & Earnings History — Annual Income Statement

Income statementTTM → 2026-03-312025-06-302024-06-302023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-302015-06-302014-06-302013-06-302012-06-302011-06-302010-06-302009-06-302008-06-302007-06-302006-06-30
Total Revenue$1.2B$1.2B$1.2B$1.1B$1.1B$931M$739M$714M$643M$563M$499M$452M$358M$311M$315M$290M$269M$264M$257M$223M$203M
Gross Profit$786M$790M$770M$770M$756M$633M$483M$473M$432M$375M$337M$307M$251M$231M$236M$225M$215M$208M$205M$177M$157M
Gross Margin %65.0%64.8%66.4%67.7%68.4%68.0%65.4%66.3%67.2%66.5%67.5%67.9%70.3%74.4%75.0%77.6%79.8%79.0%79.5%79.1%77.4%
Operating Income (EBIT)$154M$102M$207M$299M$297M$237M$157M$126M$136M$122M$151M$147M$160M$158M$166M$163M$156M$151M$144M$124M$109M
Operating Margin %12.7%8.4%17.8%26.3%26.8%25.5%21.3%17.6%21.2%21.6%30.2%32.5%44.6%51.0%52.8%56.2%58.1%57.1%56.0%55.5%53.5%
Net Income$110M$73M$168M$285M$272M$140M$229M$96M$125M$77M$104M$108M$111M$113M$112M$112M$110M$105M$104M$85M$73M
Net Margin %9.0%6.0%14.5%25.1%24.6%15.1%31.0%13.5%19.5%13.7%20.9%23.8%31.0%36.2%35.7%38.7%40.8%39.9%40.2%38.1%36.2%
EBITDA$258M$217M$313M$457M$414M$250M$378M$212M$201M$182M$193M$184M$179M$173M$175M$174M$165M$159M$152M$137M$115M
Earnings Per Share (EPS)$0.70$0.46$1.05$1.76$1.66$0.87$1.45$0.62$0.82$0.52$0.70$0.72$0.75$0.76$0.76$0.76$0.73$0.69$0.66$0.54$0.46
Shares Outstanding (M)157M160M161M162M164M162M158M156M152M150M149M149M148M148M148M149M149M152M157M158M158M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

TECH Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-30
Total Revenue$311M$296M$287M$317M$316M$297M$289M$306M
Gross Profit$208M$191M$188M$199M$215M$194M$183M$203M
Gross Margin %66.9%64.6%65.6%62.7%67.9%65.3%63.2%66.4%
Operating Income (EBIT)$75M$54M$48M($24M)$39M$47M$40M$46M
Operating Margin %24.2%18.4%16.6%-7.5%12.2%16.0%13.8%15.0%
Net Income$51M$38M$38M($18M)$23M$35M$34M$41M
Net Margin %16.4%12.8%13.3%-5.6%7.1%11.8%11.6%13.3%
EBITDA$99M$78M$75M$6M$68M$72M$70M$72M
Earnings Per Share (EPS)$0.33$0.24$0.24$-0.11$0.14$0.22$0.21$0.25
Shares Outstanding (M)157M157M156M156M159M161M161M161M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

TECH Free Cash Flow History

Cash flowTTM → 2026-03-312025-06-302024-06-302023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-302015-06-302014-06-302013-06-302012-06-302011-06-302010-06-302009-06-302008-06-302007-06-302006-06-30
Cash from Operations (CFO)$295M$288M$299M$254M$325M$352M$205M$182M$170M$143M$144M$139M$137M$124M$127M$127M$111M$111M$115M$91M$86M
Capital Expenditures (CapEx)$25M$31M$63M$38M$45M$44M$52M$25M$21M$15M$17M$20M$14M$22M$6M$4M$5M$7M$16M$8M$5M
Free Cash Flow (FCF)$270M$257M$236M$216M$280M$308M$153M$156M$149M$128M$127M$119M$123M$101M$121M$124M$107M$105M$99M$82M$81M
FCF Margin %22.3%21.0%20.4%19.0%25.4%33.1%20.8%21.9%23.2%22.8%25.4%26.4%34.4%32.6%38.4%42.6%39.6%39.7%38.4%36.9%40.0%
Dividends Paid$50M$50M$50M$50M$50M$50M$49M$48M$48M$47M$48M$47M$45M$43M$41M$40M$38M$28M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

TECH Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-30
Cash from Operations (CFO)$87M$82M$28M$98M$41M$84M$64M$75M
Capital Expenditures (CapEx)$9M$6M$5M$5M$10M$7M$9M$18M
Free Cash Flow (FCF)$78M$76M$22M$93M$31M$78M$55M$58M
FCF Margin %24.9%25.9%7.8%29.4%9.8%26.1%18.9%18.8%
Dividends Paid$13M$12M$12M$12M$13M$13M$13M$13M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

TECH Balance Sheet History

Balance sheet2026-03-312025-06-302024-06-302023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-302015-06-302014-06-302013-06-302012-06-302011-06-302010-06-302009-06-302008-06-302007-06-302006-06-30
Total Assets$2.6B$2.6B$2.7B$2.6B$2.3B$2.3B$2.0B$1.9B$1.6B$1.6B$1.1B$1.1B$862M$778M$719M$618M$519M$472M$507M$455M$371M
Cash & Cash Equivalents$210M$162M$152M$181M$173M$199M$147M$101M$122M$92M$64M$55M$319M$164M$117M$78M$99M$161M$167M$135M$90M
Total Liabilities$465M$639M$635M$672M$594M$692M$646M$719M$514M$606M$250M$216M$67M$41M$45M$32M$17M$16M$20M$17M$30M
Total Debt (Short + Long-Term)$214M$360M$332M$361M$268M$353M$366M$505M$348M$350M$95M$77M$13M$0M$0M$0M$0M$0M$0M$0M$13M
Total Shareholders' Equity$2.1B$1.9B$2.1B$2.0B$1.7B$1.6B$1.4B$1.2B$1.1B$951M$879M$847M$795M$738M$674M$586M$502M$456M$487M$438M$340M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive TECH viewer.

Other Companies in Life Sciences Tools & Services

← TEAMAll stocksTECK →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.